Amgen Proprietary - Confidential
PRIME -HF 
Confidential  Version 3 – July 19, 2017  1 Predischa Rge Initiation of Ivabradine in the Management of 
Heart Failure (PRIME -HF) 
Date: July 19, 2017  
Version: 3 
[STUDY_ID_REMOVED]
Principal Investigator : Robert J. Mentz, MD  
Duke Clinical Research Institute  
CONFIDENTIALITY STAT EMENT  
The information contained in this document is the property or under control of DUKE CLINICAL 
RESEARCH INSTITUTE ( DCRI) and is provided to you in confidence as an investigator, potential 
investigator, or consultant, for review by you, your staff, and an applicable Institutional Review Board or 
Independent Ethics Committee.   The information is only to be used by you in conne ction with the clinical 
Amgen Proprietary - Confidential  
PRIME -HF 
   
 
Confidential  Version 3 – July 19, 2017  
 2 study described in the protocol.   You will not disclose any of the information to others without written 
authorization from  DCRI . 
 
 
 
 
Protocol Version and Amendment Tracking  
Version Number/Amendment  Approval Date  
  
Version 1  May  2, 2016  
Version 2  June 2 9, 2016  
Version 3  July 19, 2017  
 
 
 
 
 
Amgen Proprietary - Confidential  
PRIME -HF 
   
 
Confidential  Version 3 – July 19, 2017  
 3 Protocol Synopsis  
Name of Study Sponsor  Dr. Robert Mentz, Duke Clinical Research Institute  
Product  Ivabradine  
Protocol  Title Predischarge Initiation of Ivabradine in the Management of 
Heart Failure  
Main Criteria for Inclusion  Acute HF hospitalization  
Study  Objective  To test the primary hypothesis that, compared with usual care, 
a treatment strategy of initiation of ivabradine prior to 
discharge for a hospitalization for acute HF will result in a 
greater proportion of participants using ivabradine at 180 days.  
To explore barriers to acqui sition of new HF therapies in 
routine clinical practice.    
Study  Design  A multi -center, patient -level, randomized, open -label study of 
180 days duration  following index hospitalization in 
approximately 450 patients.   
Treatment  Regimen  Pre-discharge initi ation of twice -daily oral ivabradine (starting 
at 5mg BID with encouraged dose titration to 7.5mg BID) 
versus usual care (i.e., post -discharge initiation of ivabradine at 
discretion of routine physician) for 180 days.  Patients 
randomized to pre -discharge ivabradine who are not able to 
afford medication will enter a registry of ivabradine -eligible 
paitents with documentation of medication acquisition 
challenges.  
Duration  of Study Participation  180 days  
Number  of Subjects  Approximately 450 
Number  of Sites Approximately 50 US  
Primary  Endpoint  Proportion of participants taking ivabradine at 180 days  
Secondary  Endpoints  Heart Rate Assessments: change in heart rate from baseline to 
180 days; heart rate at 180 days; and proportion of patients 
with heart rate < 70 bpm at 180 days  
Amgen Proprietary - Confidential  
PRIME -HF 
   
 
Confidential  Version 3 – July 19, 2017  
 4 Name of Study Sponsor  Dr. Robert Mentz, Duke Clinical Research Institute  
Product  Ivabradine  
Changes in symptoms and quality of life from baseline to 180 
days by KCCQ and PGA  
 
  
Amgen Proprietary - Confidential  
PRIME -HF 
   
 
Confidential  Version 3 – July 19, 2017  
 5 Table of Contents  
 
Protocol Version and Amendment Tracking  ................................ ................................ ...2 
Protocol Synopsis ................................ ................................ ................................ .......... 3 
Table of Con tents  ................................ ................................ ................................ .......... 5 
Abbreviations ................................ ................................ ................................ ................ 9 
Executive Summary  ................................ ................................ ................................ .... 10 
1 Introduction  ................................ ................................ ................................ ..... 16 
1.1 Background  ................................ ................................ ..........................  16 
1.2 Prior data ................................ ................................ ..............................  17 
1.3 Rationale  ................................ ................................ ..............................  18 
2 Objectives ................................ ................................ ................................ ........  19 
2.1 Primary Obje ctive  ................................ ................................ .................  19 
2.2 Secondary Objectives ................................ ................................ ............  19 
2.3 Tertiary Objectives  ................................ ................................ ...............  19 
3 Subject Selection  ................................ ................................ .............................  21 
3.1 Study Population  ................................ ................................ ..................  21 
3.2 Inclusion Criteria  ................................ ................................ ..................  21 
3.3 Exclusion Criteria  ................................ ................................ .................  22 
4 Study Design  ................................ ................................ ................................ ... 24 
4.1 Overview of Study  ................................ ................................ ................  24 
4.2 Screening Phase ................................ ................................ ....................  24 
4.3 Clinical Evaluation Prior to Randomization  ................................ ...........  24 
Amgen Proprietary - Confidential  
PRIME -HF 
   
 
Confidential  Version 3 – July 19, 2017  
 6 4.4 Randomization  ................................ ................................ .....................  25 
Figure 1. Study Flow Diagram  ................................ ................................ .....................  26 
 26 
Figure 2. Schematic of Study Design  ................................ ................................ ...........  27 
4.5 Treatment Arms ................................ ................................ ....................  27 
4.6 Patient Safety and Concomitant Medical Therapy  ................................ .. 27 
5 Study Procedures  ................................ ................................ .............................  29 
5.1 Screening and Prerandomization Procedures  ................................ ..........  29 
5.2 Baseline Evaluations  ................................ ................................ .............  29 
5.3 Treatment Intervention ................................ ................................ ..........  29 
5.4 Follow -up Evaluations  ................................ ................................ ..........  30 
5.4.1  Clinical Follow -up Visit (Study Visit 1)  ................................ .. 30 
Table 1. Recommended Dose Adjustments for Patients Taking Ivabradine  ....................  30 
5.4.2  Clinical Follow -up Visit (Study Visit 2)  ................................ .. 30 
5.4.3  Phone Call ................................ ................................ ..............  31 
5.4.4  Final Study Visit (Study Visit 3)  ................................ .............  31 
5.5 Schedule of Assessments  ................................ ................................ ...... 33 
6 Enrollment and Randomization ................................ ................................ .........  34 
6.1 Enrollment ................................ ................................ ............................  34 
6.2 Randomization  ................................ ................................ .....................  34 
7 Participant safety  ................................ ................................ .............................  35 
7.1 Patient Safety and Concomitant Therapies  ................................ .............  35 
7.2 Institutional Review Boards  ................................ ................................ .. 35 
7.3 Informed Consent  ................................ ................................ .................  35 
7.4 Study Discontinuation ................................ ................................ ...........  35 
Amgen Proprietary - Confidential  
PRIME -HF 
   
 
Confidential  Version 3 – July 19, 2017  
 7 8 Adverse Event Reporting and Follow -up................................ ...........................  37 
8.1 Safety  ................................ ................................ ................................ ... 37 
8.2 Definitions ................................ ................................ ............................  37 
8.2.1  Events of Interest ................................ ................................ .... 37 
8.3 Protocol Specific Exceptions to SAE Reporting  ................................ ..... 38 
8.3.1  Suspected Adverse Reaction  ................................ ...................  38 
8.4 Assessment of Adverse Event Severity  ................................ ..................  39 
8.5 Assessment of Causal Relationship ................................ ........................  39 
8.6 Expectedness  ................................ ................................ ........................  40 
8.7 Adverse Event Reporting  ................................ ................................ ...... 40 
8.8 Serious Adverse Events ................................ ................................ .........  40 
8.9 Pregnancy ................................ ................................ .............................  41 
8.10  Withdrawal of Subjects from Study  ................................ .......................  41 
9 Summary of clinical events  ................................ ................................ ..............  42 
10 Statistical Analysis Plan and Determination of Sample Size ...............................  43 
10.1  Overview ................................ ................................ ..............................  43 
10.2  Sample Si ze Justification  ................................ ................................ ...... 43 
10.3  Analysis of the Primary Endpoint  ................................ ..........................  44 
10.4  Analysis of Secondary and Tertiary Endpoints  ................................ ....... 44 
10.5  Interim Analyses ................................ ................................ ...................  45 
11 Data Monitoring and Quality Control ................................ ................................  46 
11.1  Required Data ................................ ................................ .......................  46 
11.2  Data Collection and Tracking  ................................ ................................  46 
12 Study Responsibilities  ................................ ................................ ......................  48 
12.1  Investigator Responsibility/Performance ................................ ................  48 
12.2  Study Data Reporting and Processing  ................................ ....................  48 
12.3  Training  ................................ ................................ ...............................  48 
Amgen Proprietary - Confidential  
PRIME -HF 
   
 
Confidential  Version 3 – July 19, 2017  
 8 12.4  Monitoring the Investigational Sites  ................................ ......................  49 
12.5  Study Documentation ................................ ................................ ............  50 
12.6  Source Documentation  ................................ ................................ ..........  50 
12.7  Protocol Deviations  ................................ ................................ ..............  52 
12.8  Data Transmittal and Record Retention  ................................ .................  52 
12.9  Study Closeout  ................................ ................................ .....................  53 
12.10  Audit/Inspections ................................ ................................ ..................  53 
12.11  Publication Policies  ................................ ................................ ..............  53 
13 Ethical Considerations ................................ ................................ ......................  54 
13.1  Informed Consent  ................................ ................................ .................  54 
13.2  Confidentiality of Subjects  ................................ ................................ .... 54 
13.3  Authorization for Use and Disclosure of Protected Health Information 
(HIPAA)  ................................ ................................ ..............................  55 
13.4  Human Subject Protections  ................................ ................................ ... 55 
13.4.1  Research Subject Selection and Justification of Exclusions  ...... 55 
13.4.2  Risks/Discomforts o f Study Participation  ................................  55 
13.5  Institutional Review Board/Ethics Committee Review  ...........................  55 
13.6  Steering Committee  ................................ ................................ ..............  56 
13.7  Data and Safety Monitoring Board  ................................ ........................  56 
14 Appendices  ................................ ................................ ................................ ...... 57 
Appendix A. Safety Considerations ................................ ................................ ..............  57 
Appendix B. Cardiomyopathy Questionnaire and Patient Global Assessment  ................  58 
References  ................................ ................................ ................................ ..................  59 
 
  
Amgen Proprietary - Confidential  
PRIME -HF 
   
 
Confidential  Version 3 – July 19, 2017  
 9 Abbreviations  
bpm Beats per minute  
DSMB  Data Safety Monitoring Board  
ECG Electrocardiogram  
HF Heart Failure  
HFrEF  Heart failure with reduced ejection fraction  
IRB Institutional Review Board  
IV Intravenous  
KCCQ  Kansas City Cardiomyopathy Questionnaire  
LVEF  Left Ventricular ejection fraction  
NYHA  New York Heart Association  
PGA  Patient Global Assessment  
  
  
  
 
Amgen Proprietary - Confidential  
PRIME -HF 
   
 
Confidential  Version 3 – July 19, 2017  
 10  
Executive Summary  
Title  Predischa Rge initiation of Ivabradine in ManagEment of Heart Failure (PRIME -
HF) 
Patient 
Population  Post-Acute Heart Failure Syndrome with left ventricular ejection fraction (LVEF) 
<35%, New York Heart Association (NYHA) class II -IV symptoms despite 
guideline -directed medical therapy, documented clinical stability, and sinus rhythm 
with a resting heart rate of >70 beats per minute (bpm).  
Location  Approximately 50  clinical centers in the United States  
Brief Rationale  Heart failure (HF) affects over 5 million adults in the United States alone and the 
prevalence is expected to increase.1 Despite promising advances in the treatment of 
chronic heart failure with reduced ejection fraction (HFrEF),2 patient outcomes 
remain poor, especially after a hospitalization for HF, and there is an unmet need for 
novel treatment strategies. Previous data also suggest that the hospital setting may 
provide a unique opportunity for patients with HF to initiate guideline -directed 
medical therapy.3 
Ivabradine is an orally available, specific inhibitor of the If current in the sinoatrial 
node recently approved for use for patients with HF rEF by the Food and Drug 
Administration. A double -blind, randomized, placebo -controlled trial demonstrated 
that h eart-rate reduction with ivabradine improves clinical outcomes for patients with 
chronic, symptomatic HF.4 The initiation of ivabradine specifically  in patients 
following stabilization for acute HF has not been evaluated.  
Since ivabradine was FDA approved relatively recently, this study also serves as a 
strategy trial to explore drug acquisition for a drug that has been proven efficacious 
to the heart failure popu lation and has been added to 2016 ACC/AHA/HFSA  
Amgen Proprietary - Confidential  
PRIME -HF 
   
 
Confidential  Version 3 – July 19, 2017  
 11 guidelines, however, has not been adopted broadly into clinical practice. Ivabradine 
is not being provided for this study. Data are  being captured to assess the number of 
subjects able to obtain ivabradine pre  and post discharge as well as the barriers to 
obtaining ivabradine  and reasons for non -initiation.  
Study Design  A multi -center, patient -level, randomized, open -label study of 180 days duration  
following index hospitalization in approximately 450 patients.  Given barriers to 
adoption of relatively novel therapeutics into clinical practice, those patients who are 
randomized to pre -discharge ivabradine but are not able to afford medication will 
enter a registry of ivabradine -eligible patients with doc umentation of the medication 
acquisition challenges experienced by the patient and provider.  
Treatment  Pre-discharge initiation  of twice -daily oral ivabradine (starting at 5mg BID with 
encouraged dose titration to 7.5mg BID) versus usual care (i.e., post -discharge 
initiation of ivabradine at discretion of routine physician) for 180 days.   
Primary 
Objective  To test the primary hypothesis that, compared with usual care, a treatment strategy of 
initiation of ivabradine prior to discharge for a hospitalization for acute HF will be 
associated with a greater proportion of participants using ivabradine at 180 days.   
Secondary 
Objectives  To assess the impact of pre discharge initiation of ivabradine  on: 
1) Heart Rate  
a) Change in heart rate from baseline to 180 days  
b) Median heart rate at 180 days  
2) Patient -Centered Outcomes  
a) Kansas City Cardiomyopathy Questionnaire  (KCCQ)  
b) Patient Global Assessment  (PGA)  
Tertiary 
Objectives  To explore the impact of pre discharge initiation of ivabradine on:  
1) Evidence -Based Implementation  
a) Assessments of beta -blocker use at 180 days (e.g., proportion on beta -
blocker, proportion on target dose, mean change in dose)  
Amgen Proprietary - Confidential  
PRIME -HF 
   
 
Confidential  Version 3 – July 19, 2017  
 12 b) Other assessments of ivabradine use at 180 days (e.g., mean dose, proportion 
with any initiation, proportion on maximum dose)  
i) Evaluations will incorporate data based on whether or not indication 
status was retained and whether or not an ivabradine prescrip tion was 
provided.  
2) Tolerability of ivabradine and events of interest  
a) Symptomatic bradycardia  
b) Symptomatic hypotension  
c) Other symptoms leading to ivabradine discontinuation  
To explore barriers to ivabradine acquisition in routine clinical practice.  
Summary  of 
Clinical Events  1) Worsening HF defined as hospital admission for worsening signs and/or 
symptoms of HF or receiving unplanned intravenous (IV) diuretics for HF as an 
outpatient  
2) All-cause mortality  
Primary 
Endpoint  Proportion of participants taking ivabrad ine at 180 days . 
Secondary 
Endpoints  1) Heart Rate Assessments  
a) Change in heart rate from baseline to 180 days  
b) Heart rate at 180 days  
c) Proportion of patients with heart rate <70bpm at 180 days  
2) Changes in symptoms and quality of life from baseline to 180 days as assessed 
by: 
a) KCCQ  
b) PGA  
Tertiary 
Endpoints  1) Beta-blocker use at 180 days as assessed by the (a) proportion of participants on 
a beta -blocker at 180 -days, (b)  proportion on target dose, (c)  the proportion 
Amgen Proprietary - Confidential  
PRIME -HF 
   
 
Confidential  Version 3 – July 19, 2017  
 13 discontinuing beta -blockers at 180 days and (d) the mean change in beta -blocker 
dose from discharge to 180 days  
2) Ivabradine use at 180 days as assessed by the (a) proportion of appropriate 
participants with any initiation of ivabradine at 180 days, (b) the proportion of 
appropriate participants at the maxim um dose of ivabradine at 180 day  (i.e., 7.5 
mg twice daily) , and (c) the mean dose of ivabradine achieved at 180 days  
3) Tolerability of ivabradine and events of interest : 
a) Symptomatic bradycardia  
b) Symptomatic hypotension  
c) Other symptoms leading to ivabradine di scontinuation  
4) Summary of barriers to acquisition of ivabradine.  
Summary of 
Clinical Events  1) Worsening HF defined as hospital admission for worsening signs and/or 
symptoms of HF or receiving unplanned intravenous (IV) diuretics for HF as an 
outpatient  
2) All-cause mortality  
Abbreviated 
Study Flow  1) Patients with a reduced LVEF ( <35%) will be identified during a hospitalization 
with acute HF. Patients will be screened throughout the hospital stay though 
heart rate will specifically be assessed following stabilization . 
2) Prior to discharge, clinical stability will be assessed including blood pressure and 
heart rate  criteria . Patients with a pre -discharge blood pressure of >90/50 mm Hg 
and heart rate > 70 bpm will be eligible and consent will be obtained. Subject 
should not have a planned/scheduled up -titration of beta -blocker in the following 
4 weeks. However, adjustments of background therapy can be made at any point 
during the study period at the discretion of the treating physician.  Patients can be 
consent ed and randomized prior to the day of discharge as long as they meet 
entry criteria.  
Amgen Proprietary - Confidential  
PRIME -HF 
   
 
Confidential  Version 3 – July 19, 2017  
 14 3) Consented patients will undergo baseline examination, KCCQ, and PGA. 
Baseline heart rate will be assessed on at least one 12-lead ECG  (screening ECG 
may be used).  
4) Participants will then be randomized to pre discharge initiation of ivabradine or 
usual care. Randomization will be stratified by clinical site .  
5) Participants  randomized to pre discharge initiation of ivabradine should receive at 
least the initial dose of 5m g BID prior to discharge from the hospital  if possible . 
6) If the patient is randomized to pre -discharge initiation, the study team and/or 
inpatient care team (e.g., providers and care coordinator) should initiate the 
process to acquire outpatient medication,  explore patient costs and consider 
support options for the patient. If the patient is not able to pay for the medication, 
they will continue in the study and will enter a registry of ivabradine -eligible 
patients with documentation of the medication acquis ition challenges 
experienced by the patient and provider.  
7) Consistent with current HF guidelines,2 all participants  should have a follow -up 
visit within 7 -14 days of hospital discharge. Heart rate and  systolic blood 
pressure will be assessed at this clinical visit. For participants randomized to 
predischarge initiation of ivabradine  and on ivabradine 5mg BID,  the heart rate 
may be used to adjust t he dose the dose to 2.5mg BID or 7.5mg BID. For 
participants randomized to usual care, ivabradine may be initiated at the 
provider’s discretion.  
8) All participants will have a second  follow -up study  visit 6  weeks  (42 +/- 14 days) 
post-discharge . Heart rate, systolic blood pressure and quality of life (KCCQ and 
PGA) will be assessed. For participants already taking ivabradine in either 
treatment group, the heart rate may again be used to adjust the dose of 
ivabradine. For participants not yet rec eiving ivabradine, it may be initiated at the 
provider’s discretion.  
9) All participants will receive a 90 (+/-7) day post -discharge  phone call  by site to 
assess for event status and tolerability of ivabradine.  
Amgen Proprietary - Confidential  
PRIME -HF 
   
 
Confidential  Version 3 – July 19, 2017  
 15 10) All participants will have a final study visit at 180 (+/-14) days post -discharge . 
Heart rate  (on exam and 1 ECG) , systolic blood pressure and quality of life 
(KCCQ and PGA) will be assessed.  The treating physician may initiate 
ivabradine per usual care clinical practice.   
Amgen Proprietary - Confidential  
PRIME -HF 
   
 
Confidential  Version 3 – July 19, 2017  
 16 1 INTRODUCTION  
1.1 Background  
Hear t failure is a major public health issue. More than 5 million Americans have HF and 
the prevalence is expected to increase as the population ages and survival from coronary, 
hypertensive, and valvular heart disease improves.1,5 Data from randomized clinical trials 
have establi shed the efficacy of a number of medical and device therapies for patients 
with chronic HFrEF,2 but patient outcomes remain poor, especially aft er a hospitalization 
for heart failure. The 1 -year mortality rate after a HF hospitalization is 20 -30%, and this 
number has been relatively unchanged over the past decade.6,7 These data suggest that 
there is an u nmet need for novel treatment strategies and supports the assessment of 
new approaches in the post -acute HF setting.  
There is also wide variation in the implementation of clinical trial evidence into 
routine practice. Previous data highlight a multi -year gap between the gener ation of new 
evidence through clinical trials and the adoption of the data into routine clinical 
practice.8,9 This gap in care translates into many unnecessary deaths and hospitalizations 
each year for patients with HFrEF.10 While there are multiple reasons for this quality gap, 
clinical inertia has most often been noted as a major barr ier. Ivabradine have been 
approved for use in Europe for several years11 for patients with symptomatic chronic 
HFrEF (LVEF <35%) and a heart rate >75 bpm on guideline -directed medical therapy (or 
intolerance/contra -indication to beta -blocker use). Ivabradine  was recently approved for 
use in the United States.  However, no US data exist regarding the potential adoption of 
ivabradine into routine clinic al care . 
Since ivabradine is a newly approved drug, this study also serves as a strategy 
trial to challenge study sites to explore drug acquisition for a drug that has been proven 
efficacious to the heart failure population and has been added to 2016 ACC/AHA/HFSA  
guidelines, however, has not been adopted rapidly into clinical practice.  Ivabradine is not 
being provided for this study. Data are being captured to assess the number of subjects 
Amgen Proprietary - Confidential  
PRIME -HF 
   
 
Confidential  Version 3 – July 19, 2017  
 17 who were able to obtain ivabradine pre and post discharge as we ll as the barriers to 
acquisition.  
Previous data for patients with HFrEF suggest that  the hospital setting may 
provide a unique opportunity for patients to initiate guideline -directed medical therapy . 
In the Initiation Management Predischarge: Process for Assessment of Carvedilol 
Therapy in HF (IMPACT -HF) study, patients with an LVEF<40% hospitalized for HF 
that were sta rted on carvedilol prior to hospital discharge were more likely to be on a 
beta-blocker at 60 days post -randomization compared to those rec eiving usual care.3 
These improvements in care were achieved without increasing side effects or index 
hospitalization length of stay. Similar to beta -blockers and other medical therapies for 
HF, ivabradine was initiall y studied in patients with chronic HF.4 The initiation of 
ivabradine  specifically  in patients following stabilization for acute HF has not been 
evaluated.  
1.2 Prior data  
The Systolic Heart failure treatment with Ivabradine Trial (SHIFT) enrolled 6,558 
patients with chronic, symptom atic heart failure with reduced ejection fraction.4 In this 
double -blind, randomized, placebo -controlled trial , patients treated with ivabradine were 
less likely to experience the primary composite endpoint of cardiovascular death or 
hospitalization for HF (HR 0.82, 95% CI 0.75 , 0.90). These results support that 
ivabradine represents a novel treatment strategy for patients with HFrEF already on 
optimal medical therapy including a beta -blocker.  
A prior study of data from the Organized Program to Initiate Lifesaving 
Treatment in H ospitalized Patients With Heart Failure (OPTIMIZE -HF) registry  suggest 
that a substantial proportion of patients hospitalized with HFrEF  have an elevated heart 
rate at discharge .12 This study analyzed 10,696 hospitalizations of pat ients with acute HF 
from United States hospitals with a LVEF  <40%. Patients with a history of atrial 
arrhythmia or with a pacemaker or cardiac resynchronization therapy  were excluded. At 
the time of discharge, t he median heart rate was 72 bpm ( interquartil e range, 65 -80 bpm) 
Amgen Proprietary - Confidential  
PRIME -HF 
   
 
Confidential  Version 3 – July 19, 2017  
 18 for patients on high -dose beta -blockers and increased to 80 bpm (interquartile range,  70-
89 bpm) for patients on no beta -blockers . Most patients, 7647 (71%), had a discharge 
heart rate of >70 bpm, including 1460 of 2301 patients (63%) d ischarged on >50% of 
target dose of beta-blocker therapy . 
1.3 Rationale  
Outcomes for patients with HFrEF remain poor after a hospitalization for HF, and there is 
an unmet need for novel treatment strategies  in HF . Previous data suggest that the 
hospital settin g may provide a unique opportunity for patients with HF to initiate 
guideline -directed medical therapy.3 
A double -blind, randomized, placebo -controlled trial demonstrated that h eart-rate 
reduction with ivabradine improves clinical outcomes for patients with chronic, 
symptomatic HF4,  but the initiation of ivabradine in patients following stabilization for 
acute HF has not been evaluated.  
 
Amgen Proprietary - Confidential  
PRIME -HF 
   
 
Confidential  Version 3 – July 19, 2017  
 19 2 OBJECTIVES  
The primary hypothesis of the PRIME -HF study is that, compared with usual care, a 
treatment strategy of initiation of ivabradine prior to discharge for a hospitalization for 
acute HF will be associated with a greater proportion of participants using ivabradine at 
180 days .  
2.1 Primary Objective  
To test the primary hypothesis that, compared with usual care, a treatment strategy of 
initiation of ivabradine prior to discharge for a hospitalization for acute HF will be 
associated with a greater proportion of participants using ivabradine at 180 days.   
2.2 Secondary Objectives  
To assess the impact of pre discharge initiation of ivabradine on:  
1) Heart Rate  
a) Change in heart rate from baseline to  180 days  
b) Median heart rate at 180 days  
2) Patient -Centered Outcomes  
a) Kansas City Cardiomyopathy Questionnaire  (KCCQ)  
b) Patient Global Assessment (PGA)  
2.3 Tertiary Objectives  
Tertiary objectives will be to explore the impact of predischarge  initiation of ivabradi ne 
on: 
1) Other assessments of evidence -based implementation of i vabradine and beta -blockers 
at 180 days . Evaluations will incorporate data based on whether or not indication 
status was retained and whether or not an ivabradine prescription was provided.  
2) Tolerability of ivabradine  based on   events  of interest  during study follow -up: 
a) Symptomatic bradycardia  
Amgen Proprietary - Confidential  
PRIME -HF 
   
 
Confidential  Version 3 – July 19, 2017  
 20 b) Symptomatic hypotension  
c) Other symptoms leading to ivabradine discontinuation  
3) To explore barriers to the acquisition of ivabradine.  
 
Amgen Proprietary - Confidential  
PRIME -HF 
   
 
Confidential  Version 3 – July 19, 2017  
 21 3 SUBJECT SELECTION  
3.1 Study Population  
Patients suitable for this protocol are individuals with chronic HF who are hospitalized 
with acute heart failure , have achieved clinical stability  and have an LVEF <35% and 
heart -rate >70 bpm  in normal sinus rhythm . Subject s should not have a 
planned/scheduled uptitration of beta -blocker in the following 4 weeks. Adjustments of 
background therapy can be made at any point during the study period at the discretion of 
the attending physician.  
3.2 Inclusion Criteria  
To be eligible for the study  subject m ust meet the inclusion criteria listed below:  
1) Hospitalized with a cute HF  (primary or secondary diagnosis) based on clinician 
assessment   
2) A prior clinical diagnosis of HF  (i.e., not a new diagnosis of heart failure  during 
the current hospitalization ) 
3) Most recent LVEF ≤ 35% and within 6 months of randomization  or LVEF ≤ 25% 
within 12 months of randomization  
4) On optim al guideline -directed medical therapy for HFrEF (or previously deemed 
intolerant)  as determined by the clinician  including ACE -inhibitors or angiotensin 
receptor antagonists  or neprilysin inhibition,  aldosterone receptor antagonists, and 
maximally -tolerated doses of beta -blockers at the time of current evaluation 
(which may differ from long -term targets)  
 Maximally -tolerated doses of beta -blockers will be defined by the treating 
physician when considering aspects such as current dose relative to the target 
dose used in clinical trials, patient heart rate and blood pressure, and patient 
symptoms   
 Patients with intoler ance or contraindication to beta -blocker use are eligible 
for enrollment (details will be documented in the case report form)  
Amgen Proprietary - Confidential  
PRIME -HF 
   
 
Confidential  Version 3 – July 19, 2017  
 22 5) Age >18 years  
6) Willingness to provide informed consent  from the subject  (or at the discretion of 
the local IRB,  the subject’s  guardian or legally authorized representative [LAR])   
7) On the day of planned randomization, all participants:  
 Must be in sinus rhythm with a resting heart rate >70 bpm as measured on  
ECG or a 10 second rhythm strip 
 Must have a blood pressure of >90/50 mm Hg 
3.3 Exclusion Criteria  
If a subject meets  any of the following criteria, he or she cannot  be enrolled in the study:  
1) Documented plan for uptitration of beta -blocker in the following 4 weeks  
2) Permanent atrial fibrillation or atrial flutter  
3) Patients with recent  atrial fibrillation or flutter defined by either precipitating the 
current HF hospitalization or occurring during the current HF hospitalization  
4) History of untreated sick sinus syndrome, sinoatrial block, or second and third 
degree atrio -ventricular block  
5) Pacemaker with atrial or ventricular pacing (except biventricular pacing) >40% of 
the time  
6) Family history or congenital long QT syndrome  
7) Recent myocardial infarction (<2 months prior to screening)  [troponin elevation 
secondary to acute HF as determined b y the clinician is not an exclusion]  
8) Acute or chronic severe liver disease as evidenced by any of the following: 
encephalopathy, variceal bleeding, INR > 1.7 in the absence of anticoagulation 
treatment  
9) Creatinine clearance <15 mL/min within 48 hours of sc reening that was not due to 
acute kidney injury that resolved  
10) Planned mechanical circulatory support  within 180 days  
Amgen Proprietary - Confidential  
PRIME -HF 
   
 
Confidential  Version 3 – July 19, 2017  
 23 11) Pregnant  or breastfeeding women . Women of child-bearing potential  should use 
effective contraception  
12) Medical conditions likely to lead to p oor non -cardiac survival at 180 days (e.g., 
cancer)  
13) Inability to comply with planned study procedures  
14) If the following medications are needed at inclusion or during the study:  
a) Non-dihydropyridine calcium channel blockers (e.g., diltiazem and verapamil)  
b) Class I anti -arrhythmics (e.g., quinidine, procainamide, lidocaine, phenytoin)  
c) Strong inhibitors of cytochrome P450 3A4 (CYP3A4), including some 
macrolide antibiotics (e.g., clarithromycin, erythromycin), cyclosporine, 
antiretroviral drugs (e.g., ritonavir , nelfinavir), and systemic azole antifungal 
agents (e.g., ketoconazole, itraconazole) , and nefazodone  
d) Inducers of cytochrome P450 3A4 (CYP3A4) including St. John’s wort , 
rifampicin, barbiturates, and phenytoin . 
e) Treatments known to be associated with signi ficant prolongation of the QT 
interval, including sotalol  
 
Amgen Proprietary - Confidential  
PRIME -HF 
   
 
Confidential  Version 3 – July 19, 2017  
 24 4 STUDY DESIGN  
4.1 Overview of Study  
The PRIME -HF study is a multi -center, patient -level, randomized, open -label study of 
approximately 450 patients with reduced LVEF of <35% and heart -rate >70 bpm who a re 
being discharged from the hospital following  stabilization from  acute HF and will be 
randomized to a treatment strategy of predischarge  initiation of ivabradine or usual care .  
4.2 Screening Phase  
Patients admitted with acute HF will be screened for basic e ntry criteria. To be eligible, 
patients should be hospitalized with a cute HF (primary or secondary diagnosis) . Patients 
hospitalized with acute HF will be treated with standard therapy at the discretion of the 
treating physician including adjustment of guideline -directed medical therapies such as 
beta-blockers. Patients will be screened for potential eligibility  during the index 
hospitalization but study inclusion  criteria including clinical stability, heart rate, and 
blood pressure will be assessed once the patient is stable and approaching discharge.  
Patients can be consented and randomized prior to the day of dis charge as long as they 
meet entry criteria.  
4.3  Clinical Evaluation Prior to Randomization  
When patients are approaching the time for  discharge, final study eligibility will be 
determined. Prior to discharge, clinical  stability  will be assessed to ensure reso lution of 
signs and symptoms of acute HF. Blood pressure and resting heart rate will be assessed. 
Patients with a pre -discharge blood pressure of >90/50 mm Hg and heart rate > 70 bpm 
will be eligible and approached for consent. Subject s should not have a 
planned/scheduled uptitration of beta -blocker in the following 4 weeks. Willing 
participants meeting entry criteria will provide written informed consent.  Baseline heart 
rate must be ≥70bpm on ECG or a 10 -second rhythm strip.  
Amgen Proprietary - Confidential  
PRIME -HF 
   
 
Confidential  Version 3 – July 19, 2017  
 25 4.4  Randomizat ion 
After signing the informed consent form, all subjects who fulfill all of the inclusion 
criteria and none of the exclusion criteria will be randomized. All patients will be 
randomized using an electronic system in a 1:1 allocation  ratio to either predis charge  
initiation of ivabradine or usual care. Randomization will be stratified by clinical site.   
 
 
 
 
 
 
 
 
 
 
 
  
Amgen Proprietary - Confidential  
PRIME -HF 
   
 
Confidential  Version 3 – July 19, 2017  
 26 Figure 1. Study Flow Diagram  
 
 
 
 
  
 
 
  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Screening  
 LVEF <35% and h ospitalized  for acute HF (primary or secondary diagnosis)  
 Treated with standard therapy at the discretion of the treating physician including beta -blockers  
Patient Deemed Eligible for Discharge  
 Obtain i nformed consent  
 BP > 90/50 mm hg and sinus rhythm with a resting heart rate >70 bpm on a 12-lead ECG or 10 -second rhythm strip   
 Obtain baseline exam,  KCCQ, PGA (obtain ECG if not already completed in screening)  
Baseline/ Randomization (Day 0)  
 1:1 randomization to pre discharge initiation of ivabradine or usual care  
Predischarge Initiation (n=225)  Usual Care (n=225)  
 
In-Hospital Monitoring  
 Patients randomized to predischarge initiation receive 1st dose of 
ivabradine 5mg BID prior to hospital discharge. Explore medication costs 
and options to support patient.  
Post -discharge Follow -up (7 -14 days post -
discharge) (Follow up Visit 1)  
 Assess  current  medication us e/doses , heart 
rate, KCCQ, PGA, event status  
 Dose titration of ivabradine  
 
Week 6 Follow -up Visit (42 ± 14 days ) (Follow up Visit 2)  
 Assess  current medication us e/doses , heart rate, KCCQ, PGA, event status  
 If participant now on ivabradine:  
o If heart rate <50 or symptomatic bradycardia, decrease ivabradine dose  
o If heart rate 50 -60, maintain ivabradine dose  
o If heart rate >60, increase ivabradine dose  
 If participant not on ivabradine , it may be initiated at the provider’s discretion  
  
Day 90 Phone Call (± 7  days)  (Follow up Phone Call)  
 Assess current heart failure medication use/doses, event status and tolerability of ivabradine in all participants  
 
Day 180 Follow -up Visit (± 14  days)  (Follow up Visit 3)  
 Assess  current medication us e/doses , heart rate via ECG, KCCQ, PGA, event status , and the final dose of ivabradine prior to the visit  Post -discharge Follow -up (7 -14 days post -
discharge) (Follow up Visit 1)  
 Assess  current medication us e/doses , heart 
rate, KCCQ, PGA, event status  
 Ivabradine may be initiated at the 
provider’s discretion  
 
Amgen Proprietary - Confidential  
PRIME -HF 
   
 
Confidential  Version 3 – July 19, 2017  
 27 Figure 2. Schematic of Study Design  
 
4.5 Treatment Arms  
The treatment arms for this study are p re-discharge initiation of twice -daily oral 
ivabradine (starting at 5mg BID with encouraged dose titration to 7.5mg BID) versus 
usual care (i.e., post -discharge initiation of ivabradine at discretion of routine physician) 
for 180 days.  
4.6 Patient Safety and C oncomitant Medical Therapy  
Patients will receive standard medical therapy throughout the study. Adjustments of 
background therapy can be made at any point during the study period at the discretion of 
the attending physician. Therapy may include diuretics, ACE -inhibitors or ARBs, 
neprilysin inhibition, beta-blockers, and mineralocorticoid receptor antagonists. Patients 
may have adjustments of beta -blocker therapies up until 24 hours prior to 
randomization and still be eligible for the study . Subject should n ot have a 
planned/scheduled uptitration of beta -blocker in the following 4 weeks . 

Amgen Proprietary - Confidential  
PRIME -HF 
   
 
Confidential  Version 3 – July 19, 2017  
 28 Sites will report  events of i nterest  to include SAE s related to Ivabradine, Pregnancy, or 
lactation exposure .  Additional details are found in Section 8.  
Amgen Proprietary - Confidential  
PRIME -HF 
   
 
Confidential  Version 3 – July 19, 2017  
 29 5 STUDY PROCEDURES  
5.1 Screening and Prerandomization Procedures  
Potentially eligible  subjects will be identified f rom inpatient admissions  and screened by 
interview. Interested subjects will be asked to give written informed consent and undergo 
a screening evaluation to include  a complete history, physical examination, and laboratory 
tests. Study personnel will assess each subject against each inclusion and each exclusion 
criterion, and the investigator will determine the subject’s eligibility for study participation. 
The inform ed consent process and all assessments will be documented in the subject’s 
medical record.  
5.2 Baseline Evaluations  
At the baseline visit and the time of randomization (prior to administration of ivabradine ), 
all study participants will undergo the following:  
 History and physical examination  
 Baseline heart rate assessment via ECG  (if ECG not already obtained in 
screening)  
 KCCQ and PGA  
5.3 Treatment Intervention  
Participants randomized to predischarge  initiation of ivabradine should receive the first 
dose of medication prior to discharge  if possible . If ivabradine is administered and then 
discharge is delayed, participants should continue on open -label ivabradine  until hospital 
discharge.  Participants should then receive a prescription for outpatient ivabradin e. Study 
drug will not be provided as part of the study.  If the patient is randomized to pre -
discharge initiation, the study team and/or inpatient care team (e.g., providers and care 
coordinator) should initiate the process to acquire outpatient medication , explore patient 
costs and consider support options for the patient. If the patient is not able to pay for the 
medication, they will continue in the study and will enter a registry of ivabradine -eligible 
Amgen Proprietary - Confidential  
PRIME -HF 
   
 
Confidential  Version 3 – July 19, 2017  
 30 patients with documentation of the medication acqui sition challenges experienced by the 
patient and provider.  All participants will be counseled on the signs and symptoms of 
bradycardia including lightheadedness, dizziness, and syncope. Participants will also be 
followed carefully for the remainder of the hospitalization and monitored for adverse 
events including bradycardia or recurrence of heart failure signs or symptoms.   
5.4 Follow -up Evaluations  
5.4.1 Clinical Follow -up Visit (Study Visit 1)  
Consistent with current HF guidelines,2 all participants  should have a follow -up study 
visit within 7 -14 days of hospital discharge . The timing of this visit will be determined by 
treating physicians. Current medication use and doses, physical examination, heart rate, 
systolic blood pressure and quality of life (KCCQ and PGA) will be assessed at this 
clinical visit. For participants randomized to pre discharge initiation of ivabradine  and on 
5mg BID , the heart rate may be used to adjust the dose of ivabradine to 2.5mg BID or 
7.5mg BID (Table  1). For participants randomized to usual care, ivabradine may be 
initiated at the provider’s disc retion. Participants not eligible for ivabradine at th is visit 
will be document ed and continue study follow -up.  
Table 1. Recommended Dose Adjustments for Patients Taking Ivabradine  
Heart Rate  Dose Adjustment  
>60 bpm  Increase dose by 2.5 mg (given twice daily) up to a maximum 
dose of 7.5mg twice daily  
50-60 bpm  Maintain current dose  
<50 bpm or signs and 
symptoms of bradycardia  Decrease dose by 2.5mg (given twice daily); if current dose is 
2.5 mg twice daily, then discontinue therapy  
5.4.2 Clinical Follow -up Visit ( Study Visit 2 ) 
At 6 weeks  (42 +/- 14 days) post-discharge , all participants will have  follow -up study 
visit. The study visit will include an assessment of c urrent medication use and doses,  
Amgen Proprietary - Confidential  
PRIME -HF 
   
 
Confidential  Version 3 – July 19, 2017  
 31 physical examination,  heart rate, and systolic blood pressure . For participants on 
ivabradine, the heart rate may be used to adjust the dose (Table  1). For participants with a 
resting heart rate >60 bpm, the dose may be increased to either 5mg or 7.5mg BID. If the 
resting heart rate is <50 bpm or the partici pant is experiencing signs or symptoms related 
to bradycardia, then the dose may be reduced to 2.5mg BID or the study drug should be 
discontinued. If the heart rate is 50 to 60 bpm, then the dose may be maintained. For 
participants not yet taking ivabradin e, then it may be initiated at the provider’s discretion. 
Participants not eligible for ivabradine at th is visit will be documented and continue study 
follow -up. Study investigators or designee will assess  quality of life (KCCQ and PGA ).  
5.4.3  Phone Call  
At 90  (+/-7) days post -discharge , participants should be contacted by the site ( phone call )  
to assess for event status, c urrent medication use and doses,  and tolerability of ivabradine , 
specifically  
  Symptomatic bradycardia  
 Symptomatic hypotension  
 Other symptoms leading to ivabradine discontinuation  
  
5.4.4  Final Study Visit  (Study Visit 3)  
At 180 (+/- 14) days post discharge , all participants will have a routine clinic visit . The 
visit will include an assessment of c urrent medication use and doses, physical 
examination  including  heart rate  assessment (by exam and 1 ECG ), and systolic blood 
pressure . The final dose of ivabradine prior to the visit will be recorded. P articipants 
never  initiated on or  eligible for ivabradine will also be recorded . The study inve stigators 
or designee will assess  quality of life (KCCQ and PGA ).  
 
Using the  study schedule of assessments , provider -determined heart rate will be assessed 
at the following time points: baseline, post -discharge clinical follow -up visit ( within 7 -14 
Amgen Proprietary - Confidential  
PRIME -HF 
   
 
Confidential  Version 3 – July 19, 2017  
 32 days of hospital discharge ), week 6, and day 180. Patient quality of life assessment will 
be assessed at the following time points: baseline, post -discharge clinical follow -up visit 
(within 7 -14 days of hospital discharge ), week 6, and day 180.  
Amgen Proprietary - Confidential  
PRIME -HF 
   
 
Confidential  Version 3 – July 19, 2017  
 33 5.5 Schedule of Assessments  
 
 
 
 
 
 
 
  Baseline  
Time (Day)  Pre-discharge  Day 7 -14 
post 
discharge  6 Weeks post -
discharge  
(42 +/- 14 
days ) 90 Days post -
discharge   
(+/-7 days)  180 Days 
post-
discharge 
(+/- 14 days)  
      
Visit  Baseline /Randomization  FU Visit 
1 FU Visit 2  FU Phone 
Call FU Visit 3  
Subject consent  X     
Medical History  X     
Physical examination  X X X  X 
Vital signs  (HR,BP)  X X X  X 
ECG  X    X 
KCCQ  X X X  X 
PGA  X X X  X 
Medication assessment  X X X X X 
Events of interest assessment    X X X X 
Amgen Proprietary - Confidential  
PRIME -HF 
   
 
Confidential  Version 3 – July 19, 2017  
 34 6 ENROLLMENT AND RANDOMIZATION  
6.1 Enrollment  
Eligible subjects  who have given written  informed consent and meet all inclusion and no 
exclusion criteria will be randomized .  
6.2 Randomization  
After signing the informed consent form, all subjects who fulfill all of t he inclusion 
criteria and none of the exclusion criteria will be randomized. All patients will be 
randomized using an electronic system in a 1:1 allocation  ratio to either predischarge  
initiation of ivabradine or usual care. Randomization will be stratified by clinical site.   
Amgen Proprietary - Confidential  
PRIME -HF 
   
 
Confidential  Version 3 – July 19, 2017  
 35 7 PARTICIPANT SAFETY  
7.1 Patient Safety and Concomitant Therapies  
This study will evaluate and compare pre -discharge initiation of ivabradine versus usual 
care in patients stabilized after an acute HF exacerbation  requiring hospital ization . 
Although investigators are encouraged to follow the assigned treatment strategy, in all 
cases the patient’s safety based on the clinical judgment of the treating physician will 
take priority over the specific treatment assignment. Concomitant ther apies will be at the 
discretion of the treating physician. All subjects will receive standard of care which can 
be adjusted by their usual care provider(s) during the study accord ing to clinical need.  
Usual care providers will be encouraged to follow the most up to date guidelines for 
cardiovascular care based upon local and institutional practice patterns and relevant 
published practice guidelines.  
7.2 Institutional Review Boards  
All sites will submit the  study protocol, informed consent form, and other relevant study 
documents to their Institutional Review Board (IRB) for approval.  
7.3 Informed Consent  
All patients will have the purpose of the study, the study interventions and evaluations, 
and the potentia l risks and benefits of participation explained to them and their questions 
answered. If they consent to participation in this study, they will review and sign the 
informed consent form.  
7.4 Study Discontinuation  
Subjects may withdraw at any time during the s tudy without prejudice or be discontinued 
from study treatment at the discretion of the investigator if medically necessary . In 
addition, a subject may be wi thdrawn by the investigator or  the sponsor if the subject 
violates the study plan or for administrative and/or other safety reason.   
Amgen Proprietary - Confidential  
PRIME -HF 
   
 
Confidential  Version 3 – July 19, 2017  
 36 The investigator or designee will document in the eCRF when a subject has been 
discontinued or withdrawn from study treatment because of an adverse experience.  When 
a subject discontinues or is withdrawn from tre atment before  study completion, all 
applicable activities scheduled for the final study visit should be performed at the time of 
discontinuation.  Any adverse experiences that are present at the time of 
discontinuation/withdrawal should be  followed by the s ite PI until resolution.  
Amgen Proprietary - Confidential  
PRIME -HF 
   
 
Confidential  Version 3 – July 19, 2017  
 37 8 ADVERSE EVENT REPORT ING AND FOLLOW -UP 
8.1 Safety  
In this study, all medications and procedures commonly used or performed as a part of 
standard of care for the management of HF have well -defined safety profiles. For this 
trial, defined clinical endpoints and events of interest will be recorded in the eCRF. In 
addition, events that are Serious and Unexpected will be reported by a site investigator to 
the local IRB per the IRB’s instructions and will be the subject of a MedWatch re port, 
based on  local re quirements.  
 
The investigator is responsible for monitoring the safety of subjects enrolled into the 
study at the study site. The investigator or qualified designee will enter the required 
initial and follow -up information regarding events into the appropriate module of the 
eCRF .  Investigators are to report serious adverse events in accordance with their local 
IRB requirements. Investigators should follow usual clinical practices at their institution 
for reporting to regulatory autho rities serious, unexpected events related to standard of 
care medications and devices.  
8.2 Definitions  
8.2.1 Event s of Interest  
Sites will record in the eCRF Events of Interest which include  
1) Symptomatic bradycardia  
2) Symptomatic hypotension  
3) Other symptoms leading to ivabradine discontinuation  
4) Any Adverse Event that, in the opinion of the site investigator, is related to 
ivabradine and is :  
a) Serious, and  
b) Unexpected  
Amgen Proprietary - Confidential  
PRIME -HF 
   
 
Confidential  Version 3 – July 19, 2017  
 38 8.3 Protocol Specific Exceptions to SAE Reporting  
The following events  will be collected in the CRF but are not the subject of a MedWatch 
report. These events will be captured on anticipated/disease related events pages , not on 
the SAE eCRF page.  Anticipated, disease related -event in patients with acute 
decompensated heart failure  include : 
• Ventricular tachy cardia  
• Atrial fibrillation  
• Myocardial infarction  
• Acute coronary syndrome  
• Acute renal failure  
• Worsening heart failure  
• Death  
 
With the exception of the events listed above, a ll serious adverse events the site PI 
determines to be related to ivabradine must be recorded in the Serious Adverse Event 
eCRF and  should be monitored until stabilization or resolution.  
 
Site i nvestigators are responsible for knowing the local requirements for prompt reporting 
of an adverse event to the reviewing IRB/EC  and for reporting an SAE to FDA via a 
MedWatch.   
An Independent Data and Safety Monitoring Board (DSMB) will review safety composite 
data at regular intervals throughout the study. The DSMB will be empowered to stop the 
study for evidence of harm but not for evidence of efficacy .  
8.3.1 Suspected Adverse Reaction  
In PRIME -HF a  suspected adverse reaction (SAR) is any AE for which there is a 
reasonable possibility that ivabradine  caused the event. “Reasonable possibility” suggests 
there is a causal relationship betwee n the drug and the AE. “Suspected adverse reaction” 
Amgen Proprietary - Confidential  
PRIME -HF 
   
 
Confidential  Version 3 – July 19, 2017  
 39 implies a lesser degree of certainty about causality than adverse reaction, which means 
any AE caused by a drug.  
8.4 Assessment of Adverse Event Severity  
The determination of AE severity rests on medical jud gment of a medically qualified 
investigator. The severity of AEs will be graded using the following definitions:  
 Mild : Awareness of sign, symptom, or event, but easily tolerated.  
 Moderate : Discomfort enough to cause interference with usual activity and 
may warrant intervention.  
 Severe : Incapacitating with inability to do usual activities or significantly 
affects clinical status and warrants intervention.  
8.5 Assessment of Causal Relationship  
A medically qualified investigator must assess the relationship of an y AE to the use of 
study drug, based on available information, using the following guidelines:  
 Not related : There is not a reasonable causal relationship between the 
investigational product and the AE.  
 Unlikely related : No temporal association or cause of  the event has been 
identified, or the drug or biologic cannot be implicated.  
 Possibly related : There is reasonable evidence to suggest a causal 
relationship between the drug and AE.  
 Probably related : There is evidence to suggest a causal relationship betw een 
the drug and AE, and the influence of other factors is unlikely.  
Amgen Proprietary - Confidential  
PRIME -HF 
   
 
Confidential  Version 3 – July 19, 2017  
 40 8.6 Expectedness  
The Investigative site PI or designee will determine expectedness of an SAE according to 
the package insert for U.S. marketed ivabradine . Any SAE that is not identified in nature, 
severity, or specificity in the current study drug reference documents  is considered 
unexpected. Events that are listed  in the package insert  as occurring with a class of drugs 
or as anticipated from the pharmacological properties of the drug, but not specifically 
listed  as occurring with the particular drug under investigation, are considered 
unexpected.  As per the ivabradine package insert, th e most common adverse reactions 
occurring in ≥ 1% of patients are bradycardia, hypertension, atrial fibrillation and 
luminous phenomena (phosphenes).  
8.7 Adverse Event Reporting  
All SAEs obtained via direct subject reporting and/or clinical staff observation  that the 
site PI determined to be related to ivabradine will be captured within the electronic case 
report form ( eCRF ). 
8.8 Serious Adverse Events  
The investigator must re cord, via the EDC system , all SAEs  that the site PI determined to 
be related to ivabradine  occurring at visit 1  through visit 3  within 24 hours of knowledge 
of the event. If the eCRF system is temporarily unavailable, notify the sponsor or 
designee of the event, including investigator -determined causality assessment, via a paper 
back-up SAE for m. Upon return of the availability of the EDC system, the SAE 
information must be entered into the eCRF.  
 
The investigator must re cord in the EDC system  when important follow -up information 
(final diagnosis, outcome, results of specific investigations, etc .) becomes available after 
submission of the initial SAE information. Follow -up information should be submitted 
according to the same process used for reporting the initial event as described above (i .e., 
Amgen Proprietary - Confidential  
PRIME -HF 
   
 
Confidential  Version 3 – July 19, 2017  
 41 within 24 hours of knowledge, via the EDC system ). All SAEs will be followed until 
resolution, stabilization, until otherwise explained .  
 
Research sites are expected to follow  local IRB policies and procedures for reporting 
AEs/SAE s.  
8.9 Pregnancy  
During the course of the trial, if any female subject  who is receiving ivabradine become s 
pregnant, or if any person is exposed to ivabradine by a lactating female subject , this 
information  will be recorded in the eCRF  and reported via the pregnancy form .  While a 
subject’s pregnancy is not considered an SAE, it must be reported within the same 
timelines as an SAE  (within 24 hours) .  Any AEs or SAEs associated with ivabradine that 
occur to the female subject  or fetus/child will be recorded in the eCRF on the AE or SAE 
form, as appropriate.  
8.10 Withdrawal of Subjects f rom Study  
Subjects have the right to withdraw from the study at any time and for any reason without 
prejudice to future medical care. In the case of subject withdrawal, the investigator will 
discuss with the subject the most appropriate way to terminate st udy participation to 
ensure the subject’s health. All efforts will be made to complete and report the 
observations as thoroughly as possible up to the date of study termination. All applicable 
activities scheduled for the final study visit should be prefor med at the time of 
discontinuation. Randomized subjects who withdraw from the study will not be replaced.  
 
 
 
Amgen Proprietary - Confidential  
PRIME -HF 
   
 
Confidential  Version 3 – July 19, 2017  
 42 9 SUMMARY OF CLINICAL EVENTS  
Additional data on clinical events of interest will be collected.  
a. Worsening HF defined as  either hospital admission for  worsening signs and/or 
symptoms of HF or receiving unplanned intravenous (IV) diuretics for HF as 
an outpatient . 
b. All-cause mortality  
 
 
Amgen Proprietary - Confidential  
PRIME -HF 
   
 
Confidential  Version 3 – July 19, 2017  
 43 10 STATISTICAL ANALYSIS PLAN AND  DETERMINATION OF SA MPLE 
SIZE  
10.1 Overview  
All planned analyses will be prospectively defined for this study and approved by the 
Steering Committee. In addition, exploratory analyses will be performed to help explain 
and understand findings observed from the planned analyses. Statistical tests with a 2 -
sided p -value <0.05 will be considered statist ically significant, unless otherwise stated. 
Analyses will be performed using SAS software (SAS Institute, Inc, Cary, NC).   
The primary endpoint of the study is proportion of participants using ivabradine at 180 
days.  
10.2 Sample Size Justification  
We assumed that 35% of participants randomized to the usual care arm will be treated 
with ivabradine at 180 days, and the predischarge initiation of ivabradine would increase 
the use at 180 days to 50%. The usual care event rate is  based on investigator estimates of 
clinical use in the first year following approval by the Food and Drug Administration. At 
a two -sided Type I error rate of 0.05, 450 participants would provide 85% power to 
detect a significant difference in the rate of ivabradine use between groups. This sample 
size estimate is based on a two -group continuity corrected chi -square test and assume s a 
1:1 allocation ratio between the predischarge initiation of ivabradine and usual care 
groups . This sample size estimate allow s for 8% missing primary endpoint data. 
 
For the KCCQ overall summary endpoint we have made a conservative assumption of 16 
points for the standard deviation.  For this measure, the m edium and large clinically 
meaningful differences are 5 and 10 points for the KCCQ overall summary measure, 
respectively.  Allowing for approximately 8% missing data, the proposed sample size of 
450 participants provides approximately 90% power to detect a difference of 5 points 
Amgen Proprietary - Confidential  
PRIME -HF 
   
 
Confidential  Version 3 – July 19, 2017  
 44 (medium clinically meaningful difference). The power calculations are based on the two 
sample t -test with a two -sided Type I error rate of 0.05.  
10.3 Analysis of the Primary Endpoint  
The primary analysis will be conducted on an intention -to-treat (ITT) basis including all 
randomized  participants . A log istic regression model with ivabradine use at 180 days as 
the binary outcome variable and indicator variables for treatment group main effects and 
category of baseline beta -blocker use . The treatment effect for the ivabradine at discharge 
group will be sum marized by the odds ratio and the associated 95% confidence interval.   
10.4 Analysis of Secondary and Tertiary Endpoints  
 Heart Rate Assessments  
o Change in heart rate from baseline to 180 days  across treatment groups.  
Change will be calculated as follows: (Baseli ne heart rate – 180-day heart 
rate). Comparisons across treatment groups will be performed using a 
linear model with adjustment for the baseline heart rate and beta-blocker 
use.  Treatment groups will be included in the regression model as main 
effects . Multiple imputation will be used to impute 180 -day missing HR 
observations  if missing is > 10% . 
o Heart rate  in bpm  at 180 days will be compared in the predischarge 
ivabradine group compared across treatment groups. Comparisons across 
treatment groups will be performed using a linear model with adjustment 
for the baseline heart rate and beta-blocker use.  Treatment groups will be 
included in the regression model as main effects . Multiple imputation will 
be used to imp ute 180 -day missing HR observations  if missing is > 10% . 
 Changes in symptoms and quality -of-life from baseline to 180 days as assessed by  
KCCQ  and PGA will be evaluated across treatment groups using a linear model 
with adjustment for the baseline quality -of-life and beta -blocker use. A multiple 
imputation approach will be used to account for possible missing data. The 
Amgen Proprietary - Confidential  
PRIME -HF 
   
 
Confidential  Version 3 – July 19, 2017  
 45 differences between treatment groups will be estimated using point estimates and 
the associated two -sided 95% confidence intervals.  
 Beta-blocker use at 180 days as assessed by the (a) proportion of participants on a 
beta-blocker at 180 -days, (b)  proportion on target dose, (c)  the proportion 
discontinuing beta -blockers at 180 days and (d) the mean change in beta -blocker 
dose from discharge to 18 0 days  will be compared between treatment groups.  
 Ivabradine use at 180 days as assessed by the (a) proportion of appropriate 
participants with any initiation of ivabradine at 180 days, (b) the proportion of 
appropriate participants at the maximum  dose of ivabradine at 180 day  (i.e., 7.5 
mg twice daily) , and (c) the mean dose of ivabradine achieved at 180 days  will be 
compared between treatment groups.  
 The event counts and subject incidences for the following adverse events will be 
presented for the treatment groups:  
o Symptomatic bradycardia  
o Symptomatic hypotension  
 Barriers to the acquisition of ivabradine. Barriers will be documented in the case 
report form and reported in tabular format.  
10.5 Interim Analyses  
Interim data analysis for efficacy will no t be conducted due to modest  size and short 
duration of this study. Safety data will be periodically assessed by the DSMB.  
Amgen Proprietary - Confidential  
PRIME -HF 
   
 
Confidential  Version 3 – July 19, 2017  
 46 11 DATA MONITORING AND QUALITY CONTROL  
11.1 Required Data  
The full study dataset will be collected for subjects who enter the randomization  phase of 
the st udy. Limited data as available (i.e., demographics, serious adverse events  related to 
ivabradine , selection criteria, and reason for discontinuation) will be collected for subjects 
who discontinue before  the end of the protocol specified follow -up period . 
All required data for this study will be entered into the electronic case report form (eCRF).  
11.2 Data Collection  and Tracking  
Qualified study staff at each site will perform primary data collection from source -
document reviews.  The sponsor o r designee  will perform clinical monitoring, including 
review of eCRFs with verification to the source documentation.  
This study will use Web-based e-CRFs developed through a validated, electronic reporting -
electronic -signatures –compliant platform (21 C ode of Federal Regulations  Part 11 ). The 
investigator's site staff who will be entering data will receive training on the system, after 
which each person  can set up their database account and request study access  
For security reasons, and in compliance with r egulatory guidelines, it is imperative that 
only the person s who own the user IDs and password s access the system using their own 
unique access codes.  Access codes are non transferable. Site personnel who have not 
undergone training may not use the system a nd will not be granted access to the clinical 
database until appropriate training is completed.  
During monitoring visits, the site will make their computer and/or high -speed Internet 
access available to the clinical research associate , so that he  or she may verify the data 
entries with the source documentation.  At the conclusion of the study, each enrolling site 
will be provided with a thumb drive containing PDF files of both the individual subject's 
Amgen Proprietary - Confidential  
PRIME -HF 
   
 
Confidential  Version 3 – July 19, 2017  
 47 data and the audit trail (changes made to the database) . This will be maintained at the site 
according to the requirements for records retention.  
Amgen Proprietary - Confidential  
PRIME -HF 
   
 
Confidential  Version 3 – July 19, 2017  
 48 12 Study Responsibilities  
12.1 Investigator  Responsibility/Performance  
The site principal investigator (PI) agrees  to be responsible for implementing and 
maintaining quality  control  and quality assurance systems to ensure that all work incidental 
to this protocol is  conducted and data are generated, documented, and reported in 
compliance with : the protocol ; accepted standards of Good Clinical Practice  (GCP) ; and 
all applicabl e federal, state, and local laws, rules and regulations relating to the conduct of 
the clinical study.  
The PI will provide current copies of the study protocol to all subinvestigator s or other site 
personnel responsible for study conduct.  
The PI will provide the sponsor or designee  with copies of all institutional review board 
(IRB) actions regarding the study.  
12.2 Study Data Reporting and Processing  
Each page of the  electronic case report form  (eCRF) will be reviewed by PI at the site.  The 
PI is required to sign the eCRF on the appropriate pages to verify that he  or she has 
reviewed the recorded data.  This review and sign -off may be delegated to a qualified 
physician appointed as a subinvestigator  by the PI. The transfer of duties to a 
subinve stigator  will be recorded on the delegation list , which is  kept on file at the site. The 
investigator must ensure that all site staff involved in the conduct of the trial are familiar 
with the protocol and all study -specific procedures, and that they have appropriate 
knowledge of the study agents.  
12.3 Training  
The initial training of appropriate clinical site personnel w ill be the responsibility of  the 
sponsor or designee . The PI is responsible for ensuring that staff  conduct the study 
according to the protoco l. To ensure proper administration  of study agents , uniform data  
Amgen Proprietary - Confidential  
PRIME -HF 
   
 
Confidential  Version 3 – July 19, 2017  
 49 collection, and protocol compliance, the sponsor or designee  will present a formal  
training session to study site personnel , to include instructions for study procedures, the 
investigational plan, instructions on in -hospital data collection, methods for  soliciting 
data from alternative sources, schedules for follow -up with the study site  coordinators, 
and regulatory requirements.  Detailed feedback regarding completion of  forms will be 
provided  by the sponsor ot designee  in the course of   monitoring.  
12.4 Monitoring  the Investigational Sites  
As part of a concerted effort to follow the study in a detailed and orderly manner in 
accordance with established principles  of GCP  and applicable regulations, a study monitor 
from the sponsor or designee will visit the study sites as appropriate and will maintain 
frequent telephone and written communication.  
Periodic monitoring visits may be made at all active investigational sites throughout the 
clinical study  as needed  to assure that the investigator  obligations are being fulfilled and 
all applicable regulations and guidelines are being followed. The  goal of these visits are to  
assure the facilities  are still acceptable , the protocol and investigational plan a re being 
followed, the IRB/EC has been notified of approved protocol changes as required, 
complete records are being maintained, appropriate  reports have been made to  the sponsor 
or designee  and the IRB/EC, and the investigator  is carrying out all agreed -upon activities.  
During monitoring visits, the monitor will perform a review  of  inclusion/ exclusion criteria, 
informed  consent, HIPAA authorization, events  of interest , as well as  safety and efficacy 
endpoints. Additional review will be performed on a si te-by-site basis,  as warranted by the 
findings of previous monitoring visits.  Key variables will be confirmed through review of 
source documents for a sampling of patients.  
Sites may be required to provide at a minimum the informed consent and discharge 
summary for subjects to the the sponsor or designee  via a secure system .  
Amgen Proprietary - Confidential  
PRIME -HF 
   
 
Confidential  Version 3 – July 19, 2017  
 50 Trends will be monitored and , if warranted, the frequency of onsite monitoring visits may 
be adjusted at sites .  Details will be described in the clinical monitoring plan.  
12.5 Study Docum entation  
Study documentation includes all electronic  case report forms, source documents, 
monitoring logs and appointment schedules, sponsor -investigator correspondence , and 
regulatory documents (e .g., protocol and amendments, IRB or EC correspondence and  
approval, approved and signed subject consent forms,  clinical supplies receipts and 
distribution records).  
The site PI will prepare and maintain complete and accurate study documentation in 
compliance with GCP standards and applicable federal, state, and  local laws, rules and 
regulations . For each subject participating in the study  at the site , the investigator will 
promptly complete all eCRF s and such other reports as required by this protocol following 
completion or termination of the clinical study or as otherwise required pursuant to any 
agreement with the sponsor . 
The site PI acknowledges that, within legal and regulatory restrictions and institutional and 
ethical considerations, study documentation will be promptly and fully disclosed to the 
sponsor or designee  by the investigator upon request and also shall be made available at 
the investigator’s site upon request for inspection, copying, review , and audit at reasonable 
times by representatives of the sponsor or responsible government agencies as req uired by 
law.  
The PI agrees to promptly take any reasonable steps that are requested by the sponsor or 
designee  as a result of an audit to cure deficiencies in the study documentation and eCRF s. 
12.6 Source Documentation  
Source documents include all recordings  of observations or notations of clinical activities 
and all reports and records necessary for the evaluation and reconstruction of the clinical 
Amgen Proprietary - Confidential  
PRIME -HF 
   
 
Confidential  Version 3 – July 19, 2017  
 51 study.  Accordingly, source documents include, but are not limited to, laboratory reports, 
electrocardiogram  (ECG) tracings, x-rays, radiologist reports, subject diaries, biopsy 
reports, ultrasound photographs, subject progress notes, hospital charts , pharmacy records , 
and any other similar reports or records of any procedure performed in accordance with the 
protocol.  
Whenever possible, the original recording of an observation should be retained as the 
source document; however, a photocopy is acceptable provided that it  is a clear, legible, 
and exact duplication of the original document.  
The following information will be maintained and made available as required by the 
sponsor or designee and/or regulatory inspectors:  
1. Medical history/physical condition of the study subje ct before  involvement in 
the study sufficient to verify protocol entry criteria.  
2. Document ation that informed consent was obtained for the subject’s 
participation in the study.  
3. Dated and signed notes for each subject  visit, including results of 
examinations . 
4. Notations on abnormal lab oratory  results and their resolution.  
5. Dated printouts or reports of special assessments (e .g., ECG reports).  
6. Description of adverse events (AEs) and follow -up of the AEs (minimally , 
event description, severity, onset date, durati on, relation to study drug, 
outcome , and treatment for AE). 
7. Notes regarding concomitant medications taken during the study (including 
start and  stop dates).  
Amgen Proprietary - Confidential  
PRIME -HF 
   
 
Confidential  Version 3 – July 19, 2017  
 52 8. Subject’s  condition upon completion of or withdrawal from the study.  
12.7 Protocol Deviations  
A protocol deviation is defined as an event where the investigator  or site  personnel did not 
conduct the study according to the investigational plan. Site investigators must also follow 
the policy of the reviewing IRB for reporting such deviations. to thei r reviewing IRB per 
local policy.  
The IRB/EC will be informed of all protocol changes by the sponsor or the investigator in 
accordance with applicable regulations and the IRB/EC’s established procedures.  No 
deviations from the protocol of any type will be made without complying with the 
IRB/EC’s established procedures.  
Investigator s will  maintain document ation of  the dates and reasons for each deviation from 
the protocol.  
12.8 Data Transmittal and Record Retention  
Required data will be entered in the eCRF at the  time of or as soon as possible after the 
subject visit or the availability of test results  
The PI will maintain  final eCRFs, worksheets, and all other study -specific documentation  
(e.g., study f ile notebooks or  source documentation ) until notified by the  sponsor  that 
records may be destroyed. To avoid error, the investigator will contact the sponsor or 
designee before the destruction of any records pertaining to the study to ensure they no 
longer need to be retained. In addition , the sponsor or designee  will be contacted if the PI 
plans to leave the institution so that arrangements can be made for the transfer of records.  
The site PI takes responsibility for maintaining adequate and accurate source documents of 
all observations and data generated during th is study.  Such documentation is subject to 
inspection by the sponsor or designee  as well as by federal, state, and local  regulatory 
agencies . 
Amgen Proprietary - Confidential  
PRIME -HF 
   
 
Confidential  Version 3 – July 19, 2017  
 53 12.9 Study Closeout  
Upon completion of the study (defined as all subjects have comp leted all follow -up visits, 
all eCRFs are complete, and all queries have been resolved ), the sponsor or designee  will 
notify the site of closeout , and a study closeout visit will be performed.  All unused study 
materials can be destroyed by the site when the study is completed . The sponsor  or designee  
will ensure that the PI’s regulatory files are up -to-date and complete and that any 
outstanding issues from previous visits have been resolved.  Other issues to be reviewed at 
the closeout visit include discussing retention of study files, poss ibility of s ite audits, 
publication policy, and notifying the IRB of study closure.  
12.10  Audit /Inspections  
As needed, q uality assurance personnel from the sponsor or designee  may conduct audits 
at the study sites at a reasonable time and in a reasonable manner . Audits will include, but 
not be limited to , audit trail of data handling and processes, standard operating procedure s, 
presence of required documents, the informed consent process, and comparison of eCRF s 
with source documents.  The site PI agrees to accommodate and  participate in audits that 
are conducted . 
Regulatory authorities from the U.S. or abroad may inspect  the site during or after the study  
at a reasonable time and in a reasonable manner.  The PI should contact the sponsor  
immediatel y if contacted regarding an inspection. Site personnel are expected to cooperate 
with personnel from regulatory agencies  (e.g., FDA) audits conducted  
12.11  Publication Policies  
Members of the Steering Committee will be primarily responsible for creation, review , and 
submission of publications and presentations relating to the major aspects of the study and 
approved ancillary analyses within a timely fashion after completion of the study.  Details 
will be contained in the Publication Plan.  
 
Amgen Proprietary - Confidential  
PRIME -HF 
   
 
Confidential  Version 3 – July 19, 2017  
 54 13 Ethical Considerations  
13.1 Informed Consent  
The PI has both ethical and legal responsibility to ensure that each subject being considered 
for inclusion in this study is given a full explanation of the study.  Written informed consent 
will be obtained from all subjects (or , at the discretion of the local IRB,  the subject’s  
guardian or lega lly authorized  representative  [LAR] ) before any study -related procedures  
are performed or given.  
Written informed consent will be documented on an informed consent form (ICF) approved 
by the local IRB/EC responsible for approval of this protocol . The ICF will conform to the 
applicable requirements of 45 CFR 46 , ICH E6  and institutional requirements for informed 
consent .  The site investigator agrees to obtain approval from the sponsor  of any ICF 
intended for use in the study before  submission  of the ICF for IRB approval.  
The ICF will be reviewed with the p rospective study subject (or LAR ), and the investigator 
or qualified designee will be available to answer questions regarding procedures, risks, and 
alternatives.  
13.2 Confidentiality of Subjects  
Subject  confidentiality will be maintained throughout the clinical study in a way that 
ensures that study data  can always be tracked back to the source data.   
Subject information collected in this study will c omply with the standards for protection of 
privacy of individually identifiable health information as promulgated by the U.S. Health 
Insurance Portability and Accountability Act  (HIPAA ). All records will be kept 
confidential , and the subject’s name will not be released to persons outside the study site.  
Subject records will not be  released to anyone other than the sponsor or its designees and 
responsible regulatory authorities  when requested.  In all cases, caution will be exer cised to 
assure  the data are treated confidentially and that the subject ’s privacy is guaranteed.  
Amgen Proprietary - Confidential  
PRIME -HF 
   
 
Confidential  Version 3 – July 19, 2017  
 55 13.3 Authorization for Use and Disclosure of Protected Health Information 
(HIPAA)  
An authorization for use and disclosure of protected health information (PHI) under the 
HIPAA Privacy Rule will be obtained from every trial subject before enrollment.  The 
investigator is responsible for obtaining subjects’ (or their LAR s’) au thorizations and 
signatures  and for explaining the elements of the HIPAA authorization form , if necessary.  
The site PI will promptly inform the sponsor  of any restrictions on the use or disclosure of 
any subject’s PHI. The site investigator will also promptly inform the sponsor of written 
revocation of any subject’s HIPAA authorization.  
13.4 Human Subject Protection s 
13.4.1  Research Subject Selection and Justification of Exclusions  
There will be no exclusion from participation in the study on the basis of ethnicity or race.  
Subjects younger than 18 years of age will be excluded from the study, as the targe t 
population is adults.  Women of childbearing potential will have serum -hCG testing before  
randomization to avoid potential fetal exposure  to ivabradine .  
13.4.2  Risks/Discomforts of Study Participation  
This study will evaluate the safety and efficacy of ivabradi ne following stabilization for 
acute HF. Oral ivabradine was found to be safe and efficacious in chronic HF patients in 
the SHIFT trial over a median follow -up of 22.9 mos.  In SHIFT, the overall rate of SAEs 
was similar between the ivabradine and placebo a rms; ivabradine was not associated with 
any evidence of harm over this follow -up period.  
13.5 Institutional Review Board/Ethics Committee Review  
The appropriate IRB /EC must approve the protocol and informed consent documents, 
agree to monitor the conduct of th e study, and agree to review study progress periodically, 
Amgen Proprietary - Confidential  
PRIME -HF 
   
 
Confidential  Version 3 – July 19, 2017  
 56 at intervals not to exceed 1 year.  The investigator will provide the sponsor or designee  with 
documentation that the IRB /EC has approved the study before  the study may begin.  
In addition, the invest igator must provide the following documentation to DCRI : 
1. IRB/EC annual reapproval of the protocol,.  
2. IRB/EC approval of revisions to the informed consent documents or any 
amendments to the protocol.  The investigator will provide the sponsor or 
designee  with documentation of all approvals . 
13.6 Steering Committee  
The Steering Committee will be the primary decision making body of the study and is 
responsible for its successful completion. The Steering Committee will be comprised of 
the study  principal investigators , the project leader , and selected other investigators with 
expertise in heart failure and clinical trials.  
13.7 Data and Safety Monitoring Board  
A data and safety monitoring board (DSMB)  will be appointed for the PRIME -HF trial, 
which will include individuals with pertinent expertise in heart failure and clinical trials. 
The DSMB will advise the Steering Committee regarding  safety  concerns  for current 
participants and those yet to be rec ruited.  
 
 
Amgen Proprietary - Confidential  
PRIME -HF 
   
 
Confidential  Version 3 – July 19, 2017  
 57 14 Appendices  
Appendix A. Safety Considerations  
Similar to the SHIFT study, the following treatments are not allowed at inclusion or 
during the study:  
 Non-dihydropyridine calcium channel blockers (e.g., diltiazem and verapamil)  
 Class I anti-arrhythmics (e.g., quinidine, procainamide, lidocaine, phenytoin)  
 Strong inhibitors of cytochrome P450 3A4 (CYP3A4), including some macrolide 
antibiotics (e.g., clarithromycin, erythromycin), cyclosporine, antiretroviral drugs 
(e.g., ritonavir, nelfin avir), and systemic azole antifungal agents (e.g., 
ketoconazole, itraconazole)  
 Inducers of cytochrome P450 3A4 (CYP3A4)  including St. John’s Wort, 
rifampicin, barbiturates, and phenytoin  
 Treatments known to be associated with significant prolongation of the QT 
interval, including sotalol  
  
  
Amgen Proprietary - Confidential  
PRIME -HF 
   
 
Confidential  Version 3 – July 19, 2017  
 58 Appendix B. Cardiomyopathy Questionnaire and Patient Global Assessment  
Kansas City Cardiomyopathy Questionnaire  
The Kansas City Cardiomyopathy Questionnaire (KCCQ) is a self -administered, 23 -item 
questionnaire devel oped to provide a better description of health -related quality of life 
(QOL) in patients with heart failure. It quantifies physical limitation, symptoms, QOL, 
social interference and self -efficacy. The survey requires 4 -6 minutes to complete, and is 
scored  by assigning each response an ordinal value, beginning with 1 for the response 
that implies the lowest level of functioning and summing items within each domain. 
Scale scores are transformed to a 0 to 100 range by subtracting the lowest possible scale 
score, dividing by the range of the scale and multiplying by 100. A clinical summary 
score will be calculated by combining the functional status with the quality of life and 
social limitation domains.  
 
Patient Global Assessment  
A seven category global asses sment of clinical status that is completed by the participant 
will be utilized in the assessment of the composite score. This Patient Global Assessment 
(PGA) tool consists of the categories of: markedly improved, moderately improved, 
mildly improved, no ch ange, slightly worse, moderately worse and markedly worse.  
Participants will be asked to define their status using this tool at specified times during 
the protocol by marking their current status, relative to the baseline condition. The Patient 
Global Ass essment tool will be prepared in a manner which is simple to read (large print) 
and will be retained as a source document.   
Amgen Proprietary - Confidential  
PRIME -HF 
   
 
Confidential  Version 3 – July 19, 2017  
 59 References  
1. Mozaffarian D, Benjamin EJ, Go AS, et al. Heart Disease and Stroke Statistics —
2015 Update: A Report From the American Heart Association. Circulation. 
2015;131(4):e29 -e322.  
2. Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA Guideline for the 
Management of Heart Failure: A Report of the American College of Cardiology 
Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 
2013;128(16):e240 -e327.  
3. Gattis WA, O'Connor CM, Gallup DS, Hasselblad V, Gheorghiade M. 
Predischarge i nitiation of carvedilol in patients hospitalized for decompensated heart 
failure: results of the Initiation Management Predischarge: Process for Assessment of 
Carvedilol Therapy in Heart Failure (IMPACT -HF) trial. Journal of the American 
College of Cardiol ogy. 2004;43(9):1534 -1541.  
4. Swedberg K, Komajda M, Böhm M, et al. Ivabradine and outcomes in chronic 
heart failure (SHIFT): a randomised placebo -controlled study. The 
Lancet. 376(9744):875 -885. 
5. Braunwald E. Heart failure. JACC: Heart Failure. 2013;1(1) :1-20. 
6. Chen J, Normand SL, Wang Y, Krumholz HM. National and regional trends in 
heart failure hospitalization and mortality rates for Medicare beneficiaries, 1998 -2008. 
JAMA : the journal of the American Medical Association. 2011;306(15):1669 -1678.  
7. Loehr LR, Rosamond WD, Chang PP, Folsom AR, Chambless LE. Heart Failure 
Incidence and Survival (from the Atherosclerosis Risk in Communities Study). The 
American journal of cardiology. 2008;101(7):1016 -1022.  
8. Fonarow GC, Yancy CW, Heywood JT. Adherence to  heart failure quality -of-care 
indicators in US hospitals: analysis of the ADHERE Registry. Arch Intern Med. 
2005;165(13):1469 -1477.  
9. Peterson PN, Chan PS, Spertus JA, et al. Practice -level Variation in Use of 
Recommended Medications Among Outpatients Wi th Heart Failure: Insights From the 
NCDR PINNACLE Program. Circulation: Heart Failure. 2013.  
Amgen Proprietary - Confidential  
PRIME -HF 
   
 
Confidential  Version 3 – July 19, 2017  
 60 10. Fonarow GC, Yancy CW, Hernandez AF, Peterson ED, Spertus JA, Heidenreich 
PA. Potential impact of optimal implementation of evidence -based heart failure therapies 
on mortality. American heart journal. 2011;161(6):1024 -1030.e1023.  
11. Members ATF, McMurray J JV, Adamopoulos S, et al. ESC Guidelines for the 
diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the 
Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European 
Society of Cardiology. Developed in col laboration with the Heart Failure Association 
(HFA) of the ESC. European Heart Journal. 2012;33(14):1787 -1847.  